General
Johnson & Johnson COVID-19 vaccine under review by European Medicines Agency over blood clots
Europe’s drug regulator says it is reviewing rare blood clots in four people in the United States who received Johnson & Johnson’s COVID-19 vaccine.
Key points:
- Johnson & Johnson said it was aware of the rare reports of blood clots, and was working with regulators to assess the data
- The US Food and Drug Administration said it was aware of the reports, but they had “not found a causal relationship with vaccination”
- It follows an investigation of blood clots reported by some people given the AstraZeneca vaccine, which has prompted some countries to change their vaccine recommendations
The European Medicines Agency’s safety committee has also been looking at how AstraZeneca’s COVID-19 vaccine is associated with very rare cases of…
Continue Reading
-
General22 hours agoDriver charged after fatal alleged hit-run crash at Hillier
-
General23 hours ago‘Fortune teller’ allegedly defrauds Sydney’s Vietnamese community out of $70 million
-
Business22 hours agoOctober 2025 update boosts sales and storage
-
General17 hours agoContact tracing underway in Queensland as health authorities brace for further measles cases